Biofrontera Inc.

Good day and welcome to the BioFrontier Incorporated Third Quarter Earnings Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad. And to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Tirth Patel of Investor Relations. Please go ahead.

Thank you. Good morning and welcome to Biofrontera Inc's third quarter 2022 financial results and business update conference call. Please note that certain information discussed during today's call by management is covered under the safe harbor provisions of the Private Securities Litigation Reform Act. We caution listeners that Biofrontera's management will be making forward-looking statements and that actual results may differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. All risks and uncertainties are detailed in and qualified by the cautionary statements contained in BioFrontera's press releases and SEC filings. Also, this conference call contains time-sensitive information that is accurate only as of the date of the live broadcast, today, November 14, 2022. BioFrontera undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as required by law. During today's call, there will be references to certain non-GAAP financial measures. Biofrontera believes these measures provide useful information for investors, yet should not be considered as a substitute for GAAP, nor should they be viewed as a substitute for operating results determined in accordance with GAAP. A reconciliation of non-GAAP to GAAP results is included in this morning's press release. More specifically, management will be referencing adjusted EBITDA, a non-GAAP financial measure defined as net income or loss excluding interest income and expense, income taxes, depreciation, amortization, and certain other non-recurring or non-cash items. With that, I would like to turn the call over to Erika Monaco, Chief Executive Officer of Biofrontera, Inc. Erika?

Thank you, Ter, and welcome everyone to our third quarter conference call. Joining me today is Fred Loeffler, our newly appointed Chief Financial Officer. In a moment, Fred will review our recent financial results, and then I'll discuss the business and strategy. But first, I'd like to say a few words. I'm proud of our growing and hardworking BioFrontera team. Our third quarter results reflect the investment we've made over the past couple of quarters in strengthening medical affairs advocacy, developing our sales team and sales infrastructure, and securing our financial outlook on our path toward profitability. The feelings of momentum and teamwork at BioFrontera are palpable. During the third quarter and recent weeks, we strengthened our medical affairs initiatives with sponsorship, participation, and presentation of our innovative dermatology solutions. Through peer-to-peer interactions and other activities, dermatologists are increasingly choosing our brands for their patients. The variety of our activities and our visibility in the dermatology sector are sharpening our corporate profile as an innovative dermatology company and emphasizing our strong commitment to improving patient care in collaboration with dermatologists. Our success in strengthening patent protection for our products justifies continued investments in marketing and further clinical development. With that, I'll turn the call over to Fred to discuss our Q3 and year-to-date financial results. Fred?